Insights

Home Insights

As a partner of Chiauranib/CS2164 project, BLA Regulatory congratulates Chipscreen on receiving US FDA IND approval

As a partner of Chiauranib/CS2164 project, BLA Regulatory congratulates Chipscreen on receiving US FDA IND approval Gaithersburg, MD (03 May 2021) – BLA Regulatory, LLC, a full-service biopharma regulatory consultancy, announced that as a partner of Chiauranib/CS2164 project, BLA Regulatory congratulates Shenzhen Chipscreen Biosciences on receiving Investigational New Drug (IND) clearance from the US Food […]